ASPG and hepatic veno-occlusive disease: This particular initiative addressed 14 severe, but relatively rare toxicities, namely: hypersensitivity to asparaginase, hyperlipidemia, osteonecrosis, asparaginase-associated pancreatitis, arterial hypertension, posterior reversible encephalopathy syndrome, seizures, depressed level of consciousness, methotrexate-related stroke-like syndrome, peripheral neuropathy, high-dose methotrexate-related nephrotoxicity, sinusoidal obstructive syndrome, thromboembolism, and Pneumocystis jirovecii pneumonia.